Bioscience

Provista Life Sciences initiates validation study for Radient Pharmaceuticals

June 16, 2010

By Flinn Foundation

[Source: PR-USA] – Radient Pharmaceuticals Corporation (RPC) announced today its partner Provista Life Sciences LLC (PLS), a diagnostics development and commercialization firm based in Phoenix, Arizona, is developing requisite clinical data through a validation study of DR-70 reagents for the introduction of RPC’s Onko-Sure™ In Vitro Diagnostic (IVD) cancer test as a laboratory developed test for general cancer screening. 

For more information: Provista Life Sciences Initiates Validation Study for Radient Pharmaceuticals’ Onko-SureTM IVD Cancer